Anzeige
Mehr »
Samstag, 09.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E2CG | ISIN: CA1850534027 | Ticker-Symbol: CWY0
Tradegate
08.08.25 | 13:02
0,879 Euro
+4,33 % +0,037
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CLEARMIND MEDICINE INC Chart 1 Jahr
5-Tage-Chart
CLEARMIND MEDICINE INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,8260,85908.08.

Aktuelle News zur CLEARMIND MEDICINE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoClearmind announces patent application for metabolic syndrome treatment1
DoClearmind Medicine Inc.: Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar1
DoSciSparc Ltd: SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar1
DiClearmind Medicine Inc. - 6-K, Report of foreign issuer1
DiClearmind Medicine Inc.: Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center247IRB Approval from Hadassah Medical Center Follows FDA IND Clearance and Prior Approvals from Additional Clinical Sites Vancouver, Canada, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc....
► Artikel lesen
30.07.Clearmind files patent for obesity and liver disease treatment1
CLEARMIND MEDICINE Aktie jetzt für 0€ handeln
30.07.Clearmind Medicine Inc.: Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease2
30.07.SciSparc Ltd: SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease203TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
► Artikel lesen
29.07.Clearmind Medicine Inc. - 6-K, Report of foreign issuer1
23.07.Clearmind erweitert Studie zur Behandlung von Alkoholsucht um Standort in Tel Aviv2
23.07.Clearmind advances AUD treatment with new trial site in Tel Aviv1
23.07.Clearmind Medicine Inc.: Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder73Vancouver, Canada, July 23, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development...
► Artikel lesen
15.07.Clearmind erweitert Studie zu Medikament gegen Alkoholsucht um Standort an der Johns Hopkins University3
15.07.Clearmind expands phase I/IIa trial for alcohol use disorder treatment1
15.07.Clearmind Medicine Inc. - 6-K, Report of foreign issuer4
15.07.Clearmind Medicine Inc.: Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled1
03.07.Clearmind Gains IRB Approval At TASMC For Alcohol Use Disorder Drug Trial1
03.07.Clearmind receives IRB approval for alcohol disorder treatment trial2
03.07.Clearmind Medicine Inc.: Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center134Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development...
► Artikel lesen
30.06.Clearmind Medicine Inc. - 6-K, Report of foreign issuer2
Weiter >>
74 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1